薁磺酸钠白蛋白微球的制备及评价  

Preparation and Evaluation of Sodium Albumin Sulfonate Microspheres

作　　者：肖惠明 赵子明 XIAO Hui-ming;ZHAO Zi-ming(School of Pharmacy,Xuzhou Medical University,Jiangsu Xuzhou 221000,China)

机构地区：[1]徐州医科大学药学院,江苏徐州221000

出　　处：《广州化工》2023年第24期36-39,59,共5页GuangZhou Chemical Industry

摘　　要：采用乳化交联法制备薁磺酸钠白蛋白微球,并且通过Box-Behnken实验设计考察投药量、交联剂加入量及交联时间这三个因素对微球载药量的影响,优选最佳制备工艺。并且考察其含量及体外释药情况,测定载药量及包封率。在薁磺酸钠投药量为80 mg,交联剂用量为0.3 mL,交联时间为9 h时最优,载药量为(6.77%±0.59%)包封率为(57.55%±1.19%),平均粒径为55.55μm,并且在一定温度下稳定。体外24 h的累计释放率为95%以上。Sodium azulene sulfonate albumin microspheres were prepared by emulsification and cross-linking method.The effects of three factors,including the dosage of azulene sulfonate,the dosage of crosslinker and the cross-linking time,on the drug loading of azulene sulfonate microspheres were investigated by Box-Behnken experiment design,and the best preparation process was optimized.The content and drug release in vitro were investigated,and the drug loading and encapsulation rate were determined.When the dosage of sodium azulene sulfonate was 80 mg,the amount of cross-linker was 0.3 mL,and the cross-linking time was 9 h,the loading amount of azulene sulfonate was 6.77%±0.59%,the encapsulation rate was 57.55%±1.19%,the average particle size was 55.55μm,and it was stable at a certain temperature.The cumulative release rate of 24 h in vitro was more than 95%.

关 键 词：薁磺酸钠 白蛋白微球 Box-Behnken实验设计 稳定性 

分 类 号：R944.9[医药卫生—药剂学]